Journey Medical Corp: Form 10-Q for the period ended Jun 30, 2024
Filed with the SEC on Aug 13, 2024 and accepted by EDGAR at Aug 12, 2024, 18:21 ET.
Management's discussion and analysis
As filed, 36,410 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Certain matters discussed in this report may constitute forward-looking statements for purposes of the Securities Act of 1933, as amended (the “Securities Act”), and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the future results, performance or achievements expressed or implied by such forward-looking statements. The words “anticipate,” “believe,” “estimate,” “may,” “expect,” “will,” “could,” “project,” “should,” “intend” and similar expressions are generally intended to identify forward-looking statements. Our actual results may differ materially from the results anticipated in or implied by these forward-looking statements due to a variety of factors, including, without limitation:
- the fact that our products and product candidates are subject to time and cost intensive regulation and clinical testing and as a result, may never be successfully developed or commercialized;
- a substantial portion of our sales derive from products that are without patent protection and/or are or may become subject to third-party generic competition, the introduction of new competitor products, or an increase in market share of existing competitor products, any of which could have a significant adverse impact on our operating income;
- we operate in a heavily regulated industry, and we cannot predict the impact that any future legislation or administrative or executive action may have on our operations;
- our revenue is dependent mainly upon sales of our dermatology products and any setback relating to the sale of such products could impair our operating results;
- competition could limit our products’ commercial opportunity and profitability, including competition from manufacturers of generic versions of our products;
- the risk that our products do not achieve broad market acceptance, including by government and third-party payors;
- our reliance third parties for several aspects of our operations;
- our dependence on our ability to identify, develop, and acquire or in-license products and integrate them into our operations, at which we may be unsuccessful;
- the dependence of the success of our business, including our ability to finance our company and generate additional revenue, on the successful development and regulatory approval of the DFD-29 product candidate and any future product candidates that we may develop, in-license or acquire;
- clinical drug development is very expensive, time consuming, and uncertain and our clinical trials may fail to adequately demonstrate the safety and efficacy of our current or any future product candidates;
- our competitors could develop and commercialize products similar or identical to ours;
- risks related to the protection of our intellectual property and our potential inability to maintain sufficient patent protection for our technology and products;
- our business and operations would suffer in the event of computer system failures, cyber-attacks, or deficiencies in our or our third parties’ cybersecurity;
- the effects of major public health issues, epidemics or pandemics on our product revenues and any future clinical trials;
- our potential need to raise additional capital;
- the substantial doubt expressed about our ability to continue as a going concern;
- Fortress controls a voting majority of our common stock, which could be detrimental to our other shareholders; and
- the risks described in under the section titled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Form 10-K”).
The forward-looking statements contained in this report reflect our views and assumptions as of the effective date of this report. New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect us. Except as required by law, we assume no responsibility for updating any forward-looking statements.
We qualify all of our forward-looking statements by these cautionary statements. In addition, with respect to all of our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Overview
We are a commercial-stage pharmaceutical company founded in October 2014 that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions. Our current portfolio includes seven branded and two authorized generic prescription drugs for dermatological conditions that are actively marketed in the U.S. We are managed by experienced life science executives with a track record of creating value for their stakeholders and bringing novel medicines to the market, enabling patients to experience increased quality of life and physicians and other licensed medical professionals to provide better care for their patients. We aim to acquire rights to future products by licensing or otherwise acquiring an ownership interest in, funding the research and development of, and eventually commercializing, the products through our field sales force.
Recent Corporate Highlights
In January 2024, we summitted a New Drug Application (“NDA”) under Section 505(b)(2) of the United States Federal Food, Drug and Cosmetic Act (“FDCA”) with the U.S. Food and Drug Administration (the “FDA”) for DFD-29.
On March 18, 2024, we announced that the FDA accepted the Company’s NDA with a Prescription Drug User Fee Act (“PDUFA”) goal date of November 4, 2024.
Critical Accounting Polices and Uses of Estimates
Our discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which we have prepared in accordance with accounting principles generally accepted in the United States. Applying these principles requires our judgment in determining the appropriateness of acceptable accounting principles and methods of application in diverse and complex economic activities. The preparation of the accompanying financial statements requires us to make estimates and judgments that affect the reported amounts of revenues, expenses, assets and liabilities, and related disclosure of contingent assets and liabilities. We base our estimates on historical experience and other assumptions that we believe are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.
For a discussion of our critical accounting estimates, see the section of the 2023 Form 10-K titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies and Use of Estimates.” There were no material changes in our critical accounting estimates or accounting policies from December 31, 2023.
Accounting Pronouncements
During the six-month period ended June 30, 2024, there were no new accounting pronouncements or updates to recently issued accounting pronouncements disclosed in the 2023 Form 10-K that are expected to materially affect the Company’s present or future financial statements.
Emerging Growth Company and Smaller Reporting Company Status
We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). Under the JOBS Act, emerging growth companies can delay the adoption of new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. Other exemptions and reduced reporting requirements under the JOBS Act for emerging growth companies include presentation of only two years of audited financial statements in our annual reports on Form 10-K, an exemption from the requirement to provide an auditor’s report on internal controls over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, as amended, an exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation and less extensive disclosure about our executive compensation arrangements. We have elected to use the extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that (i) we are no longer an emerging growth company or (ii) we affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act.
We are also a “smaller reporting company,” meaning that either (i) the market value of our shares held by non-affiliates is less than $250 million or (ii) the market value of our shares held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our shares held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently completed fiscal year and the market value of our shares held by non-affiliates is less than $700 million. As a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K, we have reduced disclosure obligations regarding executive compensation, and smaller reporting companies are permitted to delay adoption of certain recent accounting pronouncements discussed in Note 2 to our consolidated financial statements in this report on Form 10-Q.
Results of Operations
The following table summarizes our results of operations for the three-month periods ended June 30, 2024 and 2023:
Comparison of the Three-Month Periods Ended June 30, 2024 and 2023
($ in thousands, except per share data)
| Revenue: | | Three-Month Periods Ended June 30, 2024 | | 2023 | | Change $% | | |
|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $14,855 | $16,961 | | $(2,106) | | -12% | ||
| Other revenue | | — | | 211 | | (211) | | -100% |
| Total revenue | | 14,855 | | 17,172 | | (2,317) | | -13% |
| | | | | | | | | |
| Operating expenses | | | | | | | ||
| Cost of goods sold – product revenue | 6,541 | 7,767 | | (1,226) | | -16% | ||
| Research and development | 913 | 1,774 | | (861) | | -49% | ||
| Selling, general and administrative | 10,328 | 12,141 | | (1,813) | | -15% | ||
| Loss on impairment of intangible assets | — | 3,143 | | (3,143) | | -100% | ||
| Total operating expenses | 17,782 | 24,825 | | (7,043) | | -28% | ||
| Loss from operations | (2,927) | (7,653) | | 4,726 | | -62% | ||
| | | | | | | | | |
| Other expense (income) | | | | | | | ||
| Interest income | (161) | (79) | | (82) | | 104% | ||
| Interest expense | | 563 | | 756 | | (193) | | -26% |
| Foreign exchange transaction losses | | 32 | | 33 | | (1) | | -3% |
| Total other expense (income) | 434 | 710 | | (276) | | -39% | ||
| Loss before income taxes | (3,361) | (8,363) | | 5,002 | | -60% | ||
| | | | | | | | | |
| Income tax expense | — | — | | — | | 0% | ||
| Net loss | | $(3,361) | | $(8,363) | | $5,002 | | -60% |
Revenues
The following table reflects our net product revenue for the three-month periods ended June 30, 2024 and 2023:
($ in thousands)
| | | Three-Month Periods Ended June 30 2024 | | 2023 | | Change $% | | |
|---|---|---|---|---|---|---|---|---|
| Qbrexza® | | $6,836 | | $8,079 | | $(1,243) | | -15% |
| Accutane® | | 5,719 | | 5,579 | | 140 | | 3% |
| Amzeeq® | | 1,205 | | 1,374 | | (169) | | -12% |
| Zilxi® | | 369 | | 572 | | (203) | | -35% |
| Other / legacy | | 726 | | 1,357 | | (631) | | -46% |
| Total net product revenue | | $14,855 | | $16,961 | | $(2,106) | | -12% |
Total net product revenues decreased by $2.1 million, or 12%, to $14.9 million for the three-month period ended June 30, 2024, from $17.0 million for the three-month period ended June 30, 2023. The decrease is primarily related to a decrease in net product revenue from Qbrexza.
Qbrexza net product revenue decreased by $1.2 million, or 15%, to $6.8 million for the three-month period ended June 30, 2024, from $8.1 million for the three-month period ended June 30, 2023. The decrease is substantially due to a decrease in unit sales volume driven by the timing of customer orders. In addition, and to a lesser extent, coupon rebates were higher as a result of the expansion of our coverage programs under our overall market access program and managed care rebates increased from the prior year quarter due to higher managed care utilization and cost increases, driving Qbrexza’s average selling price slightly lower than the prior year quarter.
Amzeeq and Zilxi combined net product revenue decreased by $0.4 million, or 19%, to $1.6 million for the three-month period ended June 30, 2024, from $1.9 million for the three-month period ended June 30, 2023. Despite increases in unit sales volume for both products, coupon and managed care rebates increased from period-to-period (See Qbrexza above) offsetting the impact of the volume increase and driving both Amzeeq and Zilxi’s average selling prices lower than the prior year quarter.
Net Revenue from our legacy products, Targadox, Exelderm, and Ximino, decreased by $0.6 million, or 46%, to $0.7 million for the three-month period ended June 30, 2024, from $1.3 million for the three-month period ended June 30, 2023. Targadox continues to experience erosion due to generic competition and we discontinued selling Ximino on September 29, 2023.
Accutane net product revenue increased by $0.1 million, or approximately 3%, to $5.7 million from the prior year quarter due to increased unit volume from the expansion of our customer and distribution base as a result of our focused selling and marketing efforts for Accutane.
Gross-to-Net Sales Accruals
We record gross-to-net sales accruals for other (chargebacks, distributor service fees, prompt pay discounts), sales returns, coupons, managed care rebates, government rebates, and other allowances customary to the pharmaceutical industry.
Gross-to-net sales accruals and the balance in the related allowance accounts for the three-month periods ended June 30, 2024 and 2023, were as follows:
($’s in thousands)
| | | Returns | | Coupons | | Managed Care Rebates | | Other | | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance as of March 31, 2024 | | $2,806 | | $2,757 | | $3,445 | | $938 | | $9,946 |
| Current provision related to sales in the current period | | 1,112 | | 23,573 | | 6,492 | | 1,722 | | 32,899 |
| Checks/credits issued to third parties | | (704) | | (24,566) | | (6,134) | | (1,631) | | (33,035) |
| Balance as of June 30, 2024 | | $3,214 | | $1,764 | | $3,803 | | $1,029 | | $9,810 |
($’s in thousands)
| | | Returns | | Coupons | | Managed Care Rebates | | Other | | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance as of March 31, 2023 | | $3,371 | | $2,217 | | $3,691 | | $2,318 | | $11,597 |
| Current provision related to sales in the current period | | 2,082 | | 25,764 | | 5,842 | | 5,231 | | 38,919 |
| Checks/credits issued to third parties | | (908) | | (30,056) | | (5,801) | | (2,796) | | (39,561) |
| Reclass coupon vendor deposit to accounts payable | | — | | 6,167 | | — | | — | | 6,167 |
| Balance as of June 30, 2023 | | $4,545 | | $4,092 | | $3,732 | | $4,753 | | $17,122 |
Gross-to-net sales accruals are primarily a function of product sales volume, mix of products sold, and contractual discounts or rebates. Our reserves for gross-to-net sales allowances were $9.8 million at June 30, 2024, compared to $9.9 million at March 31, 2024, consistent from period-to-period.
Cost of Goods Sold
Cost of goods sold decreased by $1.2 million, or 16%, to $6.5 million for the three-month period ended June 30, 2024, from $7.8 million for the three-month period ended June 30, 2023, due to the decrease in net product revenue from period-to-period.
Research and Development
Research and Development expenses decreased by $0.9 million, to $0.9 million for the three-month period ended June 30, 2024, from $1.8 million for the three-month period ended June 30, 2023. The decrease is primarily driven by lower clinical trial expenses to develop our DFD-29 product as the clinical phase of the project has concluded.
Selling, General and Administrative
Selling, general and administrative (“SG&A”) expenses decreased by $1.8 million, or 15%, to $10.3 million for the three-month period ended June 30, 2024, from $12.1 million for the three-month period ended June 30, 2023. The decrease is mainly due to our continued expense management efforts, primarily in sales and marketing and other SG&A areas, designed to improve operational efficiencies, optimize expenses and reduce overall costs.
Interest Expense, net
Interest expense decreased by $0.3 million to $0.4 million for the three-month period ended June 30, 2024, from $0.7 million for the three-month period ended June 30, 2023. The decrease is primarily attributable to a lower average principal balance outstanding during the three-months ended June 30, 2024 of approximately $15.0 million as compared to $20.0 million during the three-months ended June 30, 2023, and higher interest income resulting from increased yields.
Comparison of the Six-Month Periods Ended June 30, 2024 and 2023
($in thousands, except per share data)
| Revenue: | | Six-Month Periods Ended June 30, 2024 | | 2023 | | Change $% | | |
|---|---|---|---|---|---|---|---|---|
| Product revenue, net | | $27,885 | $29,126 | | $(1,241) | | -4% | |
| Other revenue | | — | 259 | | (259) | | -100% | |
| Total revenue | | 27,885 | 29,385 | | (1,500) | | -5% | |
| | | | | | | | | |
| Operating expenses | | | | | | | | |
| Cost of goods sold – product revenue | | 13,357 | | 14,216 | | (859) | | -6% |
| Research and development | | 8,797 | 3,807 | | 4,990 | | 131% | |
| Selling, general and administrative | | 18,748 | 25,433 | | (6,685) | | -26% | |
| Loss on impairment of intangible assets | | — | 3,143 | | (3,143) | | -100% | |
| Total operating expenses | | 40,902 | 46,599 | | (5,697) | | -12% | |
| Loss from operations | | (13,017) | (17,214) | | 4,197 | | -24% | |
| | | | | | | | | |
| Other expense (income) | | | | | | | | |
| Interest income | | (378) | (201) | | (177) | | 88% | |
| Interest expense | | 1,111 | 1,406 | | (295) | | -21% | |
| Foreign exchange transaction losses | | 53 | 80 | | (27) | | -34% | |
| Total other expense (income) | | 786 | 1,285 | | (499) | | -39% | |
| Loss before income taxes | | (13,803) | (18,499) | | 4,696 | | -25% | |
| | | | | | | | | |
| Income tax expense | | — | | — | | — | | 0% |
| Net loss | | $(13,803) | $(18,499) | | $4,696 | | -25% |
Revenues
The following table reflects our net product revenue for the six-month periods ended June 30, 2024 and 2023:
($in thousands)
| | | Six-Month Periods Ended June 30 2024 | | 2023 | | Change $% | | |
|---|---|---|---|---|---|---|---|---|
| Qbrexza® | | $11,853 | | $12,173 | | $(320) | | -3% |
| Accutane® | | 11,538 | | 10,227 | | 1,311 | | 13% |
| Amzeeq® | | 1,960 | | 2,568 | | (608) | | -24% |
| Zilxi® | | 642 | | 886 | | (244) | | -28% |
| Other / legacy | | 1,892 | | 3,272 | | (1,380) | | -42% |
| Total net product revenue | | $27,885 | | $29,126 | | $(1,241) | | -4% |
Total net product revenues decreased by $1.2 million, or 4%, to $27.9 million for the six-month period ended June 30, 2024, from $29.1 million for the six-month period ended June 30, 2023.
Net revenue from our legacy products decreased by $1.4 million, or 42%, to $1.9 million for the six-month period ended June 30, 2024, from $3.3 million for the six-month period ended June 30, 2023. Targadox continues to experience erosion due to generic competition and we discontinued selling Ximino on September 29, 2023.
Qbrexza, Amzeeq and Zilxi combined net product revenue decreased by $1.2 million, or 8%, to $14.5 million for the six-month period ended June 30, 2024, from $15.6 million for the six-month period ended June 30, 2023. The decrease is substantially due to a decrease in unit sales volume. In addition, and to a lesser extent, coupon rebates were higher as a result of the expansion of our coverage programs under our overall market access program and managed care rebates increased from the prior year due to higher managed care utilization and cost increases, driving Qbrexza, Amzeeq and Zilxi’s average selling price lower than the prior year.
Accutane net product revenue increased by $1.3 million, or 13%, to $11.5 million for the six-month period ended June 30, 2024, from $10.2 million for the six-month period ended June 30, 2023 due to increased unit volume from the expansion of our customer and distribution base as a result of our focused selling and marketing efforts for Accutane.
Gross-to-Net Sales Accruals
We record gross-to-net sales accruals for other (chargebacks, distributor service fees, prompt pay discounts), sales returns, coupons, managed care rebates, government rebates, and other allowances customary to the pharmaceutical industry.
Gross-to-net sales accruals and the balance in the related allowance accounts for the six-month periods ended June 30, 2024 and 2023, were as follows:
($'s in thousands)
| | | Returns | | Coupons | | Managed Care Rebates | | Other | | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance as of December 31, 2023 | | $4,077 | | $3,444 | | $5,210 | | $1,386 | | $14,117 |
| Current provision related to sales in the current period | | 1,240 | | 42,315 | | 11,213 | | 3,703 | | 58,471 |
| Checks/credits issued to third parties | | (2,103) | | (43,995) | | (12,620) | | (4,060) | | (62,778) |
| Balance as of June 30, 2024 | | $3,214 | | $1,764 | | $3,803 | | $1,029 | | $9,810 |
($'s in thousands)
| | | Returns | | Coupons | | Managed Care Rebates | | Other | | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance as of December 31, 2022 | | $3,689 | | $1,696 | | $3,594 | | $2,399 | | $11,378 |
| Current provision related to sales in the current period | | 4,173 | | 53,694 | | 11,414 | | 9,158 | | 78,439 |
| Checks/credits issued to third parties | | (3,317) | | (57,465) | | (11,276) | | (6,804) | | (78,862) |
| Reclass coupon vendor deposit to accounts payable | | — | | 6,167 | | — | | — | | 6,167 |
| Balance as of June 30, 2023 | | $4,545 | | $4,092 | | $3,732 | | $4,753 | | $17,122 |
Gross-to-net sales accruals are primarily a function of product sales volume, mix of products sold, and contractual discounts or rebates. Our reserves for gross-to-net sales allowances were $9.8 million at June 30, 2024, compared to $14.1 million at December 31, 2023, a decrease of $4.3 million. The decrease in the returns reserve reflects lower units on hand in the wholesaler channel. The decrease in the coupon reserve is primarily a result of the timing of receipt. The decrease in the provision for managed care is primarily due to the timing of invoices received at December 31, 2023 leading to a higher reserve at year end.
Cost of Goods Sold
Cost of goods sold decreased by $0.9 million, or 6%, to $13.4 million for the six-month period ended June 30, 2024, from $14.2 million for the six-month period ended June 30, 2023, mainly due to the decrease in net product revenue from period-to-period.
Research and Development
Research and Development expense increased by $5.0 million, to $8.8 million for the six-month period ended June 30, 2024, from $3.8 million for the six-month period ended June 30, 2023. The increase is driven by the $4.1 million filing fee payment to the FDA in January 2024 for DFD-29 and $3.0 million payment for the contractual milestone payment owed to Dr. Reddy’s Laboratories, Ltd (“DRL”) triggered by the FDA’s acceptance of our DFD-29 product NDA in March 2024. This was partially offset by lower clinical trial expenses to develop our DFD-29 product as the clinical phase of the project has concluded.
Selling, General and Administrative
Selling, general and administrative (“SG&A”) expenses decreased by $6.7 million, or 26%, to $18.7 million for the six-month period ended June 30, 2024, from $25.4 million for the six-month period ended June 30, 2023. The decrease is mainly due to our continued expense management efforts, primarily in sales and marketing and other SG&A areas, designed to improve operational efficiencies, optimize expenses and reduce overall costs.
Interest Expense, net
Interest expense decreased by $0.5 million to $0.7 million for the six-month period ended June 30, 2024, from $1.2 million for the six-month period ended June 30, 2023. The decrease is primarily attributable to a lower average principal balance outstanding during the six-months ended June 30, 2024 of approximately $15.0 million as compared to $20.0 million during the six-months ended June 30, 2023 and higher interest income resulting from increased yields.
Liquidity and Capital Resources
At June 30, 2024, we had $23.9 million in cash and cash equivalents as compared to $27.4 million of cash and cash equivalents at December 31, 2023.
On December 27, 2023, we entered into a Credit Agreement (the “Credit Agreement”) with SWK Funding LLC (“SWK”). The Credit Agreement originally provided for a term loan facility (the “Credit Facility”) in the original principal amount of up to $20.0 million. On the closing date, we drew $15.0 million. On June 26, 2024, we drew the then remaining $5.0 million under the Credit Facility. Loans under the Credit Facility (the “Term Loans”) mature on December 27, 2027, and bear interest at a rate per annum equal to the three-month term Secured Overnight Financing Rate (“SOFR”) (subject to a SOFR floor of 5%) plus 7.75%. The interest rate resets quarterly. Interest payments began in February 2024 and are paid quarterly. Beginning in February 2026, we are required to repay a portion of the outstanding principal of the Term Loans quarterly in an amount equal to 7.5% of the principal amount of funded Term Loans. The SWK Credit Facility also includes both revenue and liquidity covenants, restrictions as to payment of dividends, and is secured by substantially all assets of the Company. As of June 30, 2023, and as of the date of this Quarterly Report on Form 10-Q, the Company was in compliance with the financial covenants under the SWK Credit Facility.
On July 9, 2024, we entered into an amendment (the “Amendment”) to the Credit Agreement. The Amendment increased the original principal amount of the Credit Facility from $20.0 million to $25.0 million. The $5.0 million of additional principal added in the Amendment is contractually required to be drawn upon FDA approval of DFD-29, subject to receiving approval on or before June 30, 2025.
On December 30, 2022, we filed a shelf registration statement on Form S-3 (File No. 333-269079), which was declared effective by the Securities and Exchange Commission (“SEC”) on January 26, 2023. This shelf registration statement covers the offering, issuance and sale of up to an aggregate of $150.0 million of our common stock, preferred stock, debt securities, warrants, and units (the “2022 Shelf”). In connection with the 2022 Shelf, we entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) relating to shares of our common stock. We may offer and sell up to 4,900,000 shares of our common stock, from time to time, under the Sales Agreement. During the six months ended June 30, 2024, we issued and sold 289,744 shares of common stock under the 2022 Shelf, generating net proceeds of $1.5 million. At June 30, 2024, 3,861,553 shares remain available for issuance under the 2022 Shelf.
We regularly evaluate market conditions, our liquidity profile, and financing alternatives, including out-licensing arrangements for our products to enhance our capital structure. We may seek to raise capital through debt or equity financings to expand our product portfolio and for other strategic initiatives, which may include sales of securities under either the 2022 Shelf or a new registration statement or drawing on the SWK Credit Facility, if the conditions for the final drawdown are satisfied. We cannot make any assurances that such additional financing will be available and, if available, the terms may negatively impact the Company’s business and operations. Our expectations are based on current assumptions, projected commercial sales of our products, clinical development plans and regulatory submission timelines, which may be uncertain and may not emerge as expected. Additionally, as a result of recurring losses, substantial doubt exists about our ability to continue as a going concern for a period of at least twelve months from the date of issuance of these financial statements.
Cash Flows for the Six-Month Periods Ended June 30, 2024 and 2023
($’s in thousands)
| | | Six-Month Periods Ended June 30, 2024 | | 2023 | | Increase (Decrease) |
|---|---|---|---|---|---|---|
| Net cash (used in) provided by operating activities | | $(10,195) | | $3,013 | | $(13,208) |
| Net cash provided by (used in) investing activities | | — | | (5,000) | | 5,000 |
| Net cash provided by (used in) financing activities | | 6,668 | | (13,036) | | 19,704 |
| Net change in cash and cash equivalents | | $(3,527) | | $(15,023) | | $11,496 |
Operating Activities
Net cash flows used in operating activities for the six-month period ended June 30, 2024 were $10.2 million compared to $3.0 million of net cash flows provided by operating activities for the six-month period ended June 30, 2023, reflecting a change of $13.2 million from period-to-period. The change substantially reflects cash payments for the $4.1 million filing fee payment to the FDA in January 2024 for DFD-29 and $3.0 million for the contractual milestone payment owed to Dr. Reddy’s Laboratories, Ltd (“DRL”) triggered by the FDA’s acceptance of our DFD-29 product NDA in March 2024. The remainder was driven primarily by the changes in net working capital.
Investing Activities
Net cash used in investing activities decreased by $5.0 million from period to period. The six-month period ended June 30, 2023 reflects the $5.0 million deferred cash payment paid in January 2023 related to the Vyne Product Acquisition.
Financing Activities
Net cash flows provided by financing activities for the six-month period ended June 30, 2024 were $6.7 million compared to $13.0 million of net cash flows used in financing activities for the six-month period ended June 30, 2023, reflecting a change of $19.7 million from period-to-period. The change is driven primarily by the draw of an additional $5.0 million under the Credit Facility with SWK as well as the net proceeds from issuances of common stock under the Sales Agreement of $1.5 million as compared to the paydown of our prior letter of credit and debt facility in the prior year period.
Material Cash Requirements
In the normal course of business, we enter into contractual obligations that contain cash requirements of which the most significant currently include the following:
- We are required to make regular payments under the SWK Credit Facility. Based on the amount currently outstanding under the SWK facility and current interest rates, and assuming we do not make further draws under the SWK facility, we expect to make the following payments:
($'s in thousands)
| | | Payments by Period Total | | Remainder of 2024 | | 2025 | | 2026 | | 2027 |
|---|---|---|---|---|---|---|---|---|---|---|
| Interest | | $7,688 | | $1,337 | | $2,652 | | $2,253 | | $1,446 |
| Principal | | 20,000 | | — | | — | | 6,000 | | 14,000 |
| Exit fee | | 1,000 | | — | | — | | — | | 1,000 |
| Total | | $28,688 | | $1,337 | | $2,652 | | $8,253 | | $16,446 |
- Excluded from the above table is an additional $5.0 million under the SWB Credit Facility that is contractually required to be drawn if the FDA approves DFD-29 prior to June 30, 2025.
- Pursuant to the Vyne Product Acquisition Agreement, upon the achievement of net sales milestones with respect to the products purchased in the Vyne Product Acquisition, we are also required to pay contingent consideration consisting of a one-time payment, per product, of $10.0 million and $20.0 million upon each product reaching annual net sales of $100 million and $200 million, respectively. Each required payment must only be paid one time following the first achievement of the applicable annual net sales milestone amount.
- On June 29, 2021, we entered into the DFD-29 Agreement to obtain the global rights for the development and commercialization of DFD-29 with DRL. Based on the development and commercialization of DFD-29, additional contingent regulatory and commercial milestone payments totaling up to $155.0 million may also become payable. Royalties ranging from ten percent to twenty percent are payable on net sales of the product. In January 2024, the Company paid a $4.0 million filing fee to the FDA upon filing of an NDA for DFD-29. The Company made a $3.0 million contractual milestone payment to DRL in April 2024 based on the FDA’s acceptance of our NDA for DFD-29 filed in January 2024.
- We are contractually obligated to make installment milestone payments of $3.0 million to Ximino, all of which is classified as current.
- We are contractually obligated to make sales-based royalty payments to Dermira (for Qbrexza), Sun Pharmaceutical Industries (for Exelderm) and PuraCap Caribe (for Targadox). Due to the contingent nature of these obligations, the amounts of these payments cannot be reasonably predicted.
Market risk
As filed, 163 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.
Controls and procedures
As filed, 1,317 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness, as of June 30, 2024, of the design and operation of our disclosure controls and procedures, as such term is defined in Exchange Act Rules 13a-15(e) and 15d-15(e). Based on this evaluation, our principal executive officer and principal financial officer have concluded that, as of such date, our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
No change in internal control over financial reporting occurred during the most recent quarter with respect to our operations; which materially affected, or is reasonable likely to materially affect, our internal controls over financial reporting.
Risk factors
As filed, 584 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
We have disclosed under the heading “Risk Factors” in the 2023 Form 10-K a number of risks which may materially affect our business, financial condition or results of operations. You should carefully consider these Risk Factors and other information set forth elsewhere in this Quarterly Report on Form 10-Q. You should be aware that these risk factors and other information may not describe every risk facing our Company. Additional risks and uncertainties not currently known to us may also materially adversely affect our business, financial condition and/or results of operations.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-04-01 to 2024-06-30 | $14.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2024-01-01 to 2024-06-30 | $27.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2024-04-01 to 2024-06-30 | $6.5m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2024-01-01 to 2024-06-30 | $13.4m | us-gaap:CostOfRevenue |
| Research and development | 3 months2024-04-01 to 2024-06-30 | $913.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2024-01-01 to 2024-06-30 | $8.8m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2024-04-01 to 2024-06-30 | $10.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2024-01-01 to 2024-06-30 | $18.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2024-04-01 to 2024-06-30 | −$2.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2024-01-01 to 2024-06-30 | −$13.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2024-04-01 to 2024-06-30 | $563.0k | us-gaap:InterestExpenseNonoperating |
| Interest expense | 6 months2024-01-01 to 2024-06-30 | $1.1m | us-gaap:InterestExpenseNonoperating |
| Net income | 3 months2024-04-01 to 2024-06-30 | −$3.4m | us-gaap:NetIncomeLoss |
| Net income | 6 months2024-01-01 to 2024-06-30 | −$13.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-04-01 to 2024-06-30 | −$0.17 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2024-01-01 to 2024-06-30 | −$0.69 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-04-01 to 2024-06-30 | −$0.17 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2024-01-01 to 2024-06-30 | −$0.69 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-04-01 to 2024-06-30 | 19,993,858 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2024-01-01 to 2024-06-30 | 19,875,653 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2024-01-01 to 2024-06-30 | −$10.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2024-06-30 | $23.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-06-30 | $46.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-06-30 | $65.2m | us-gaap:Assets |
| Current liabilities | At period end2024-06-30 | $34.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-06-30 | $53.9m | us-gaap:Liabilities |
| Long-term debt | At period end2024-06-30 | $19.7m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2024-06-30 | $11.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001410578-24-001326. Last ingested by Listed: Nov 13, 2026, 16:22 ET. Listed shows no prices and gives no investment advice.